초록 ▼

The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma

The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.

대표청구항 ▼

1. A method for the prophylaxis and/or treatment of undesirable inflammatory activity in a subject which comprises administration of one or more Akkermansia muciniphila strains to the gastrointestinal tract of said subject, wherein said undesirable inflammatory activity is nongut inflammatory activi

1. A method for the prophylaxis and/or treatment of undesirable inflammatory activity in a subject which comprises administration of one or more Akkermansia muciniphila strains to the gastrointestinal tract of said subject, wherein said undesirable inflammatory activity is nongut inflammatory activity not caused by a metabolic disorder and/or obesity. 2. The method of claim 1, wherein said inflammatory activity is undesirable airway inflammatory activity, for example, of asthma including exacerbations of asthma, COPD including exacerbations of COPD and eosinophilic COPD, infection-associated inflammation, allergen-induced inflammation, allergic rhinitis or chronic rhinosinusitis. 3. The method of claim 2, wherein the undesirable inflammatory activity comprises asthma. 4. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are administered to a subject identified as having a lower than normal level of Akkermansia muciniphila in the gastrointestinal tract. 5. The method of claim 3, wherein said one or more Akkermansia muciniphila strains are administered to a subject identified as having a lower than normal level of Akkermansia muciniphila in the gastrointestinal tract. 6. The method of claim 4, wherein said subject has severe asthma. 7. The method of claim 1, wherein said subject has a systemic inflammatory disease such as rheumatoid arthritis. 8. The method of claim 1, wherein said undesirable inflammatory activity is associated with an autoimmune disorder. 9. The method of claim 1, wherein said undesirable inflammatory activity is undesirable skin inflammatory activity, for example, associated with atopic dermatitis or psoriasis. 10. The method of claim 1, wherein said undesirable inflammatory activity is undesirable inflammatory activity associated with an infection or cancer or immunotherapy thereof. 11. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are selected from a naturally-occurring Akkermansia muciniphila strain derived from human feces or biopsies, or naturally-occurring variants thereof, which have an immunomodulatory effect in the human gut. 12. The method of claim 1, wherein at least one of said one or more Akkermansia muciniphila strains is a genetically-modified mutant of a naturally-occurring Akkermansia muciniphila strain which retains immunomodulatory effect in the human gut. 13. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are administered simultaneously or sequentially with one or more probiotic strains of another bacterial species such as Lactobacillas or Bifidobacterium. 14. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are in a probiotic composition suitable for oral administration. 15. The method of claim 14, wherein said composition is a beverage or other form of nutritional composition. 16. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are in a pharmaceutical composition suitable for delivery of said one or more strains to the gastrointestinal tract. 17. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are formulated in a composition which is packaged for aerosol delivery. 18. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are administered simultaneously or sequentially with a prebiotic substance suitable for promotion of growth of Akkermansia muciniphila in the gastrointestinal tract. 19. The method of claim 1, wherein said one or more Akkermansia muciniphila strains are present in a strain-release composition and said method further comprises the pre-step of contacting said composition with a liquid, whereby said one or more strains are released into said liquid and the resulting probiotic liquid composition is ingested. 20. A method for the prophylaxis and/or treatment of undesirable inflammatory activity in a subject wherein said inflammatory activity is nongut inflammatory activity not caused by a metabolic disorder and/or obesity, said method comprising administration of a prebiotic substance, e.g. an oligofructose, so as to promote growth of Akkermansia muciniphila in the gastrointestinal tract.